Evidence map›Paper›PMID 27997993›Full record

ArticleHippocampus2017

Longitudinal imaging reveals subhippocampal dynamics in glutamate levels associated with histopathologic events in a mouse model of tauopathy and healthy mice.

Rachelle Crescenzi, Catherine DeBrosse, Ravi P R Nanga, Matthew D Byrne, Guruprasad Krishnamoorthy, Kevin D'Aquilla, Hari Nath, Knashawn H Morales, Michiyo Iba, Hari Hariharan and 3 more

Abstract read
In one paragraph

Article in Hippocampus, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed.

  1. Article
  2. Article
  3. CEST imaging combined withAlzheimer's research & therapy · 2025
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. rTg(TauFrontiers in synaptic neuroscience · 2022
    Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Non-Canonical Roles of Tau and Their Contribution to Synaptic Dysfunction.International journal of molecular sciences · 2021
    Review
  19. Review
  20. Magnetic Resonance Imaging in Tauopathy Animal Models.Frontiers in aging neuroscience · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Rachelle CrescenziDepartment of Biochemistry and Molecular Biophysics (BMB), University of Pennsylvania, Philadelphia, Pennsylvania.
Catherine DeBrosseDepartment of Biochemistry and Molecular Biophysics (BMB), University of Pennsylvania, Philadelphia, Pennsylvania.
Ravi P R NangaCenter for Magnetic Resonance and Optical Imaging (CMROI), University of Pennsylvania, Philadelphia, Pennsylvania.
Matthew D ByrneCenter for Neurodegenerative Disease Research (CNDR), University of Pennsylvania, Philadelphia, Pennsylvania.
Guruprasad KrishnamoorthyCenter for Magnetic Resonance and Optical Imaging (CMROI), University of Pennsylvania, Philadelphia, Pennsylvania.
Kevin D'AquillaCenter for Magnetic Resonance and Optical Imaging (CMROI), University of Pennsylvania, Philadelphia, Pennsylvania.
Hari NathCenter for Magnetic Resonance and Optical Imaging (CMROI), University of Pennsylvania, Philadelphia, Pennsylvania.
Knashawn H MoralesDepartment of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, Pennsylvania.
Michiyo IbaCenter for Neurodegenerative Disease Research (CNDR), University of Pennsylvania, Philadelphia, Pennsylvania.
Hari HariharanCenter for Magnetic Resonance and Optical Imaging (CMROI), University of Pennsylvania, Philadelphia, Pennsylvania.
Virginia M Y LeeCenter for Neurodegenerative Disease Research (CNDR), University of Pennsylvania, Philadelphia, Pennsylvania.
John A DetreCenter for Functional Neuroimaging (CfN), University of Pennsylvania, Philadelphia, Pennsylvania.
Ravinder ReddyCenter for Magnetic Resonance and Optical Imaging (CMROI), University of Pennsylvania, Philadelphia, Pennsylvania.

Funding

Phenotypic Diversity in COVID-19UL1TR001878 · NCATS · UNIVERSITY OF PENNSYLVANIA · PI FITZGERALD, GARRET A · 2016 to 2025
$102.4M
Institutional Clinical and Translational Science AwardUL1TR000003 · NCATS · UNIVERSITY OF PENNSYLVANIA · PI FITZGERALD, GARRET A · 2012 to 2015
$38.9M
Transgenic Mouse Models of Tau PathologiesP01AG017586 · NIA · UNIVERSITY OF PENNSYLVANIA · PI LEE, VIRGINIA M · 2000 to 2021
$37.3M
Pilot Study: POPULATION PHARMACOLOGYU54HL117798 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI GROSSER, TILO · 2012 to 2016
$18.5M
Training and DisseminationP41EB015893 · NIBIB · UNIVERSITY OF PENNSYLVANIA · PI REDDY, RAVINDER · 2012 to 2019
$11.3M
A Novel Method for Glutamate ImagingR01NS087516 · NINDS · UNIVERSITY OF PENNSYLVANIA · PI REDDY, RAVINDER · 2014 to 2018
$1.7M
NCATS NIH HHS UL1 TR000003NCATS NIH HHS UL1 TR001878NHLBI NIH HHS U54 HL117798NIA NIH HHS P01 AG017586NIBIB NIH HHS P41 EB015893NINDS NIH HHS R01 NS087516
6 · The paper itself

Abstract

Tauopathies are neurodegenerative disorders characterized by abnormal intracellular aggregates of tau protein, and include Alzheimer's disease, corticobasal degeneration, frontotemporal dementia, and traumatic brain injury. Glutamate metabolism is altered in neurodegenerative disorders manifesting in higher or lower concentrations of glutamate, its transporters or receptors. Previously, glutamate chemical exchange saturation transfer (GluCEST) magnetic resonance imaging (MRI) demonstrated that glutamate levels are reduced in regions of synapse loss in the hippocampus of a mouse model of late-stage tauopathy. We performed a longitudinal GluCEST imaging experiment paired with a cross-sectional study of histologic markers of tauopathy to determine whether (1) early GluCEST changes are associated with synapse loss before volume loss occurs in the hippocampus, and whether (2) subhippocampal dynamics in GluCEST are associated with histopathologic events related to glutamate alterations in tauopathy. Live imaging of the hippocampus in three serial slices was performed without exogenous contrast agents, and subregions were segmented based on a k-means cluster model. Subregions of the hippocampus were analyzed (cornu ammonis CA1, CA3, dentate gyrus DG, and ventricle) in order to associate local MRI-observable changes in glutamate with histological measures of glial cell proliferation (GFAP), synapse density (synaptophysin, VGlut1) and glutamate receptor (NMDA-NR1) levels. Early differences in GluCEST between healthy and tauopathy mice were measured in the CA1 and DG subregions (30% reduction, P ≤ 0.001). Synapse density was also significantly reduced in every subregion of the hippocampus in tauopathy mice by 6 months. Volume was not significantly reduced in any subregion until 13 months. Further, a gradient in glutamate levels was observed in vivo along hippocampal axes that became polarized as tauopathy progressed. Dynamics in hippocampal glutamate levels throughout lifetime were most closely correlated with combined changes in synaptophysin and GFAP, indicating that GluCEST imaging may be a surrogate marker of glutamate concentration in glial cells and at the synaptic level. © 2016 Wiley Periodicals, Inc.

Indexed as

AnimalsCell ProliferationDisease Models, AnimalDisease ProgressionGlial Fibrillary Acidic ProteinGlutamic AcidHippocampusHumansImmunohistochemistryLongitudinal StudiesMice, TransgenicNerve Tissue ProteinsNeurogliaOrgan SizeReceptors, N-Methyl-D-AspartateSynapsesGlial Fibrillary Acidic Proteinglial fibrillary astrocytic protein, mouseGlutamic AcidGprin1 protein, mouseMAPT protein, humanNerve Tissue ProteinsReceptors, N-Methyl-D-AspartateSlc17a7 protein, mouseSynaptophysinSyp protein, mousetau ProteinsVesicular Glutamate Transport Protein 1CESTgliaglutamatesynapsetauopathy

Identifiers

PMID27997993
PMCPMC5396955

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.